Moderna
Tracked across 41 events · 3545 articles · First seen Mar 09, 2018 · Last active Aug 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.
Jun 18, 2026 · 28 articles
Tech
Impact: Moderna is the clinical-stage biotechnology company developing the gene therapy SRD-002 for heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The positive DMC recommendation for its MUSIC-HFpEF trial and the ongoing MUSIC-HFrEF trial are significant milestones for the company, supporting its continued advancement in cardiovascular gene therapy.
Jun 25, 2026 · 6 articles
Business
Impact: Moderna appointed Michael Francis Crotty to its board, gaining financial expertise as it prepares for product launches.
Jul 08, 2026 · 6 articles
Business
Impact: Moderna secured a major supply contract with the International — European Commission for its RSV vaccine, enhancing its commercial prospects and competitive position against GSK and Pfizer.
Jul 09, 2026 · 6 articles
Regulatory
On August 5, 2026, the U.S. United States — Food and Drug Administration (FDA) approved Moderna's mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine, for adults aged 50 and older. The approval covers traditional approval…
Impact: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Aug 05, 2026 · 105 articles
Tech
Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for…
Impact: Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.
Aug 19, 2026 · 102 articles
Tech
Impact: Moderna>>> developed the mRNA-4194 vaccine using its mRNA technology, marking its first venture into cancer prevention, which could significantly expand its market and revenue streams.
Jun 08, 2026 · 6 articles
Tech
Impact: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.
May 22, 2026 · 36 articles
Tech
Impact: As the manufacturer of intismeran, Moderna>>> is a key beneficiary of the positive clinical trial results, which could lead to increased revenue and market share in cancer treatment. The success of intismeran validates Moderna>>>'s mRNA vaccine platform for oncology applications.
Jun 01, 2026 · 6 articles
Tech
Researchers are developing vaccines to prevent colon cancer in people with Lynch syndrome, an inherited condition that greatly increases the risk of colorectal and other cancers. At least three experimental vaccines are in development: Nouscom's…
Impact: Moderna's mRNA technology is being applied to a Lynch syndrome vaccine, potentially opening a new market and reinforcing its position in mRNA therapeutics.
Aug 06, 2026 · 20 articles
International
Impact: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.
May 21, 2026 · 627 articles
Accidents
Impact: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Accidents
The Democratic Republic of the Congo is experiencing its deadliest Ebola outbreak on record, caused by the rare Bundibugyo ebolavirus. As of August 19, 2026, the outbreak has surpassed 5,000 confirmed cases and over 2,300…
Impact: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.
Aug 01, 2026 · 295 articles
Accidents
Impact: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.
May 18, 2026 · 505 articles
Accidents
The Democratic Republic of the Congo is experiencing its largest and fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there are no approved vaccines or treatments. The outbreak, declared on…
Impact: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.
Mar 09, 2018 · 543 articles
Business
On August 20, 2026, U.S. equity markets declined sharply as rising Treasury yields, disappointing Walmart earnings, and higher oil prices weighed on investor sentiment. The Dow Jones Industrial Average fell 1.32%, the S&P 500 dropped…
Impact: Moderna fell 23.5% after surging 177% the previous day, making it the biggest decliner in healthcare.
Aug 20, 2026 · 15 articles
Accidents
The Democratic Republic of the Congo received its first shipment of more than 16,000 doses of the Ervebo Ebola vaccine on August 22, 2026, as the country battles its deadliest Ebola outbreak on record. The…
Impact: Moderna is developing an mRNA-based vaccine targeting the Bundibugyo strain, currently in clinical trials. Its progress could offer a more specific solution and enhance its vaccine portfolio.
Aug 22, 2026 · 8 articles
Business
Impact: Moderna is an immigrant-founded unicorn company that has gone public since 2016.
Jun 04, 2026 · 6 articles
Regulatory
Impact: Moderna is another pharmaceutical company that entered into advance purchase agreements with the International — European Commission, also mentioned in the context of the secret vaccine deals.
Jun 11, 2026 · 7 articles
Accidents
Impact: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.
Jun 04, 2026 · 12 articles
Business
Impact: Moderna>>> is a participating supplier in the Asian Safety and Security Online Exhibition 2026>>> (ASSOE 2026), gaining international exposure and sourcing opportunities.
Jun 01, 2026 · 7 articles
Business
Impact: Moderna's co-founder, Robert Langer, spoke at NextRise 2026 on bio innovation, indirectly associating Moderna with the event's focus on cutting-edge technologies.
Jun 26, 2026 · 8 articles
Domestic
Republican Senators Ron Johnson and Rand Paul released a batch of text messages from Dr. Anthony Fauci's government-issued phone, showing discussions in January 2021 among Fauci, CDC Director Rochelle Walensky, and Surgeon General nominee Vivek…
Impact: One of the vaccine manufacturers; similar to Pfizer, minimal direct impact.
Aug 06, 2026 · 17 articles
Domestic
Impact: Moderna is named as a donor to Vaccinate Your Family, indicating its financial support for pro-vaccine advocacy, which indirectly benefits its vaccine business.
May 18, 2026 · 7 articles
Business
Impact: Moderna co-founder Robert S. Langer's involvement as an advisor links the company to Chiron, but Moderna itself is not directly affected.
Jul 22, 2026 · 6 articles
Domestic
President Donald Trump nominated Dr. Heidi Overton, a White House domestic policy aide, to lead the U.S. United States — Food and Drug Administration (FDA). Overton, a physician and deputy director of the White House…
Impact: Moderna, a vaccine maker, had disagreements with the FDA. Overton's vaccine stance may affect future approvals.
Aug 19, 2026 · 101 articles
Tech
Impact: Moderna is mentioned in the context of a potential combination therapy with Immatics' anzu-cel, indicating future collaborative possibilities in PRAME-directed treatments.
Apr 17, 2026 · 7 articles
Business
Impact: Moderna is a partner with Vertex in developing CF treatments for patients not covered by Vertex's CFTR modulators. The acquisition does not directly affect Moderna.
Jul 06, 2026 · 34 articles
Business
On August 10, 2026, Novo Nordisk and Amazon — Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernize operations through agentic AI and cloud technologies. The agreement establishes AWS as…
Impact: Moderna is mentioned as an existing AWS customer, but this event does not directly impact it.
Aug 10, 2026 · 7 articles
Tech
Impact: Moderna is mentioned as a collaborator for a combination therapy with anzu-cel.
Jul 17, 2026 · 6 articles
+ 11 more events
View on Dashboard
100
Moderna announced trial resultsModerna Merck mRNA...
97
Moderna sought approval United States — Food and Drug AdministrationFDA Approves Moderna's...
90
Moderna partnered with Merck GroupModerna Merck mRNA...
90
Canada — Health Canada authorized clinical trial ModernaDR Congo Ebola outbreak...
90
Merck Group partnered with ModernaModerna Merck mRNA...
83
Moderna surged in tradingModerna Merck mRNA...
80
Moderna developed vaccineModerna Merck mRNA...
80
Moderna plans to file for approval United States — Food and Drug AdministrationModerna Merck mRNA...
77
United States — Food and Drug Administration refused application ModernaFDA Approves Moderna's...
75
Moderna started Phase 1 trial Canada — Health CanadaDR Congo Ebola outbreak...
75
Moderna authorized to start trial CanadaDR Congo Ebola outbreak...
71
Moderna surged in tradingUS stocks fall on yields,...
70
Moderna started clinical trialDRC Ebola outbreak spreads...
70
Moderna set to start trialLynch syndrome colon...
70
Canada approved clinical trials ModernaDRC Ebola outbreak spreads...
69
Moderna set to start trialDR Congo Ebola outbreak...
65
Moderna plan to seek approvalModerna Merck mRNA...
65
United States — Food and Drug Administration accepted application ModernaFDA Approves Moderna's...
60
Moderna developed vaccine candidateEbola vaccine doses arrive in DRC
60
Moderna expanded partnership Coalition for Epidemic Preparedness InnovationsDR Congo Ebola outbreak...
60
Moderna faced political headwinds United States — Presidency of Donald TrumpModerna Merck mRNA...
60
Coalition for Epidemic Preparedness Innovations committed funding ModernaDR Congo Ebola outbreak...
60
United States — Food and Drug Administration reversed course ModernaFDA Approves Moderna's...
60
JPMorgan Chase said launch key to profitability ModernaModerna Merck mRNA...
50
Moderna agreed to run study United States — Food and Drug AdministrationFDA Approves Moderna's...
45
Moderna withdrew combined flu-COVID shot United States — Food and Drug AdministrationFDA Approves Moderna's...
40
Moderna announced availabilityFDA Approves Moderna's...
40
Moderna submitted regulatory applications European UnionFDA Approves Moderna's...
40
Moderna submitted regulatory applications CanadaFDA Approves Moderna's...
+ 5 more actions
View on Dashboard
Vinay Prasad
regulator
↔
Moderna
Vinay Prasad, in his capacity as the former Director of the FDA's Center for Bio
Merck Group
co-developer
↔
Moderna
Moderna co-develops personalized mRNA cancer vaccines, including Intismeran, wit
Merck Group
co-developer
↔
Moderna
Merck Group co-develops personalized mRNA cancer vaccines, including Intismeran,
+ 112 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Moderna live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard